Expanding our scope to include other solid cancers, based on a case report of urothelial carcinoma featuring a NRF1–BRAF fusion that demonstrated a clinical response to trametinib,39 we have enrolled a patient with renal pelvis cancer harboring NRF1–BRAF fusion into the belvarafenib EAP program. Here, NRF1 is linked to urothelial carcinoma.